Screening for cardio-metabolic risk factors in the Romanian cohort of HIV-positive patients

Streinu‐Cercel, Anca; Săndulescu, Oana; Șchiopu, Claudiu Mihai; Streinu‐Cercel, Adrian

doi:10.1186/1471-2334-14-s7-p61

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the progress made towards the national hepatitis C elimination goal adopted in 2015 [17,18] and substantial burden of HBV infection, elimination of hepatitis B was included in the 2021-2025 Strategic Plan for the Elimination of Hepatitis in Georgia. Because of the early initiation of hepatitis C elimination efforts, Georgia's hepatitis elimination programme is further advanced than in other intermediate and high-endemicity countries in the Caucasus, Eastern Europe and Central Asia which also have a substantial hepatitis B disease burden [19][20][21][22][23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021

et al. 2023

View full text Add to dashboard Cite

Background Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. Aim We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. Methods This nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. Results Among 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. Conclusions Hepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.

show abstract